The Centers for Disease Control and Prevention (CDC) said on Tuesday it is awarding more than $3 billion to help strengthen public health workforce and infrastructure across the United States after the COVID-19 pandemic put severe stress on them.
Matthew W. Reynolds, Ph.D., vice president, scientific affairs, real world solutions, IQVIA explains how RWE evidence platforms can provide a greater picture of a disease’s progression as well as a blueprint for future outbreaks.
Britain’s medicines regulator said on Tuesday that any new or worsening reactions in patients’ eyes arising from use of Sanofi’s best-selling asthma and eczema drug Dupixent should be promptly reviewed by healthcare professionals.
Bristol Myers Squibb is terminating a seven-year-old gene therapy collaboration to develop potential treatments for congestive heart failure with uniQure N.V. valued at $1 billion.
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company for $320 million.
England’s government agency responsible for responding to public health emergencies said mistakes at a testing laboratory resulted in tens of thousands of positive COVID-19 cases reported as negative may have led to the deaths of 20 people.
One day ahead of a data presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Science reported a second patient death has been linked to Eisai and Biogen’s lecanemab.
The deal, valued at $615 million, will expand Boston Scientific’s portfolio of gastric devices.
The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease.
A Phase III trial of Axsome Therapeutics’ AXS-05 hit both the primary and secondary endpoints in patients with Alzheimer’s disease agitation, the New York-based company announced Monday.